Trifluorothymidine (TFT) is part of the novel oral formulation TAS-102, which is currently evaluated in phase II studies. Drug resistance is an important limitation of cancer therapy. The aim of the p
BackgroundColorectal cancer (CRC) is the third most common cancer worldwide, with rising incidence linked to unhealthy lifestyle habits. Although 5-fluorouracil (5-FU) remains a standard therapy, its
Dolastatin 15 is a known tubulin binding agent and shows remarkable differential cytotoxicity against a panel of colorectal HCT116 isogenic cells. The compound causes anti-vascularization effect in hu
Additional file 6: Table S4 Input and output files in LPIA. Biological pathways (FL_NL_P), biological functions (FL_NL_G) and gene transcriptional response in different conditions (FL_NL_DE) are used
